(Q39665088)

13 September 2017

title

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase (English)

1 reference

13 September 2017

11

Yung-Jue Bang

1 reference

13 September 2017

3

Seock-Ah Im

1 reference

13 September 2017

9

Do-Youn Oh

1 reference

13 September 2017

7

Sae-Won Han

1 reference

13 September 2017

10

Tae-You Kim

1 reference

13 September 2017

5

Hwang-Phill Kim

1 reference

13 September 2017

6

Young-Kwang Yoon

1 reference

13 September 2017

8

Sang-Hyun Song

1 reference

13 September 2017

2

Hyung-Seok Hur

1 reference

13 September 2017

1

Kyung-Hun Lee

1 reference

13 September 2017

Juhee Lee

4

1 reference

13 September 2017

Kyung-Hun Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727673

20 June 2024

Tae-You Kim

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727673

20 June 2024

language of work or name

English

0 references

publication date

19 August 2010

1 reference

full work available at URL

13 September 2017

https://api.elsevier.com/content/article/PII:S0304383510003794?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

https://api.elsevier.com/content/article/PII:S0304383510003794?httpAccept=text/plain

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

20 June 2024

1 reference

13 September 2017

volume

299

1 reference

13 September 2017

issue

1

1 reference

13 September 2017

page(s)

22-28

1 reference

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

13 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials

20 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy

20 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

The TOR pathway: a target for cancer therapy

20 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

mTOR-targeted therapy of cancer with rapamycin derivatives

20 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

20 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

TOR signaling in growth and metabolism

20 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Will mTOR inhibitors make it as cancer drugs?

20 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

20 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Rapamycins: mechanism of action and cellular resistance

20 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

20 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

20 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Enhanced expression of thymidylate synthase mediates resistance of uterine cervical cancer cells to radiation

20 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines

20 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer

20 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Thymidylate synthase inhibitors as anticancer agents: from bench to bedside

20 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil

20 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine

20 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors

20 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Therapy of disseminated colorectal cancer: the emerging role of intratumoral molecular biology.

20 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Significance of thymidylate synthase activity in renal cell carcinoma

20 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Clinical significance of thymidylate synthase expression in bladder cancer

20 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Establishment and characterization of human gastric carcinoma cell lines

20 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay

20 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

20 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

20 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

20 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

20 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

20 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Rapamycin's resurrection: a new way to target the cancer cell cycle

20 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Determinants of rapamycin sensitivity in breast cancer cells

20 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

20 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

20 June 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

20 June 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo

20 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo

20 June 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.020

20 June 2024

Identifiers

1 reference

13 September 2017

1 reference